The global human organoids market size is anticipated to reach USD 2.72 billion by 2030 and is projected to grow at a CAGR of 22.8% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is experiencing significant growth, driven by advancements in stem cell research and 3D cell culture technologies.
One of the key drivers of the market is the rising demand for personalized medicine. Organoids derived from patient-specific stem cells offer a unique platform for studying individual disease mechanisms and testing tailored treatment approaches. This capability is particularly valuable in oncology, where tumor-derived organoids can be used to predict patient responses to chemotherapy or targeted therapies. As healthcare shifts towards personalized treatment strategies, the adoption of organoid-based models is expected to increase, further fueling market growth.
Moreover, the growing prevalence of chronic diseases, such as cancer, neurodegenerative disorders, and liver diseases, is another major factor driving market expansion. Organoids provide an advanced model to study these conditions, leading to a deeper understanding of disease mechanisms and the development of novel therapeutic interventions. For instance, brain organoids are being used to study neurological conditions like Alzheimer’s and Parkinson’s disease, while liver and kidney organoids are helping researchers develop treatments for organ failure.
Despite these positive trends, challenges such as ethical concerns, regulatory hurdles, and high costs associated with organoid development may pose limitations to some extent. However, ongoing research efforts and technological advancements are expected to address these challenges, paving the way for the broader adoption of organoids in biomedical and clinical applications.
Request a free sample copy or view report summary: Human Organoids Market Report
Based on product, the organoid models segment dominated the market in 2024. The large share is driven by increasing drug discovery, disease modeling, and regenerative medicine adoption.
Based on organ type, the liver segment dominated the market in 2024. The large share is driven by its critical role in drug metabolism and toxicity testing.
Based on source, the adult stem cells segment led the human organoids market in 2024, driven by their widespread use in disease modeling, drug discovery, and regenerative medicine.
Based on application, developmental biology dominated the human organoids market in 2024. The large share is driven by its critical role in understanding cellular processes, tissue engineering, and organoid development.
Based on end use, the pharmaceutical & biotechnology companies held the largest market share in 2024, driven by the increasing adoption of organoid technology in drug discovery, preclinical testing, and personalized medicine.
In 2024, North America led the human organoids market, driven by strong investments in biotechnology, advanced healthcare infrastructure, and increasing adoption of organoid technology in drug discovery and personalized medicine.
Grand View Research has segmented the global human organoids market on the basis of product, source, organ type, application, end-use and region:
Human Organoids Product Outlook (Revenue, USD Million, 2018 - 2030)
Media & Supplements
Reagents
Organoid Models
Human Organoids Organ Type Outlook (Revenue, USD Million, 2018 - 2030)
Stomach Models
Intestine Models
Liver Models
Pancreatic Models
Lung Models
Brain Models
Kidney Models
Other Products
Human Organoids Source Outlook (Revenue, USD Million, 2018 - 2030)
Adult Stem Cells
Induced Pluripotent Stem Cells
Embryonic Stem Cells
Other Sources
Human Organoids Application Outlook (Revenue, USD Million, 2018 - 2030)
Developmental Biology
Drug Toxicity & Efficacy Testing
Disease Pathology
Personalized Medicine
Regenerative Medicine
Human Organoids End Use Outlook (Revenue, USD Million, 2018 - 2030)
Pharmaceutical & Biotechnology Companies
CROs & CDMOs
Academic & Research Institutes
Other End Use
Human Organoids Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
China
Japan
India
South Korea
Australia
Thailand
Latin America
Brazil
Argentina
MEA
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players in the Human Organoids Market
ATCC
Merck KGaA
STEMCELL Technologies
Corning Incorporated
Bio-Techne.
Thermo Fisher Scientific Inc.
ACROBiosystems.
PRIMACYT Cell Culture Technology GmbH
AMSBIO
Qkine Ltd.
"The quality of research they have done for us has been excellent..."